1. Home
  2. VOD vs ILMN Comparison

VOD vs ILMN Comparison

Compare VOD & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vodafone Group Plc

VOD

Vodafone Group Plc

N/A

Current Price

$16.35

Market Cap

39.1B

ML Signal

N/A

Logo Illumina Inc.

ILMN

Illumina Inc.

N/A

Current Price

$268.09

Market Cap

37.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VOD
ILMN
Founded
1984
1998
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Medical Specialities
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
39.1B
37.0B
IPO Year
1996
2000

Fundamental Metrics

Financial Performance
Metric
VOD
ILMN
Price
$16.35
$268.09
Analyst Decision
Hold
Buy
Analyst Count
4
21
Target Price
$15.72
★ $202.65
AVG Volume (30 Days)
★ 2.7M
2.3M
Earning Date
11-10-2026
10-29-2026
Dividend Yield
★ 3.11%
N/A
EPS Growth
N/A
★ 170.87
EPS
N/A
★ 2.22
Revenue
N/A
★ $4,343,000,000.00
Revenue This Year
$10.43
$6.47
Revenue Next Year
$3.46
$6.40
P/E Ratio
★ N/A
$123.85
Revenue Growth
★ N/A
N/A
52 Week Low
$11.12
$88.00
52 Week High
$17.71
$278.99

Technical Indicators

Market Signals
Indicator
VOD
ILMN
Relative Strength Index (RSI) 42.20 73.86
Support Level $14.63 $116.43
Resistance Level $16.48 N/A
Average True Range (ATR) 0.21 12.31
MACD -0.15 3.27
Stochastic Oscillator 2.24 90.76

Price Performance

Historical Comparison
VOD
ILMN

About VOD Vodafone Group Plc

Vodafone operates mobile and fixed-line networks and businesses across Europe, Africa, and the Middle East. Its largest market is Germany, where it is the second mobile operator after Deutsche Telekom and owns two cable networks after acquiring Kabel Deutschland in 2013 and Liberty Global Germany in 2019. In the UK, Vodafone merged with CK Hutchison in 2024, consolidating the mobile market. It also divested its Spanish and Italian divisions in that same year, given their low returns on invested capital.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: